secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001628280-24-015470
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024
--------------------------------------------------------------------------------

- FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.
- IND filing for FHD-909 in BRG1-mutant NSCLC on track for Q2 2024; developed with Lilly.
- Selective CBP degrader demonstrates tumor growth inhibition in solid tumors without thrombocytopenia or anemia.
- Selective EP300 degrader shows efficacy in prostate cancer and DLBCL models with no platelet effects.
- Conference call today at 5 pm ET to review pipeline updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024015470/0001628280-24-015470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828024015470/fhtx-20240409.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-015470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer